MedPath

Screening for Genes in Patients With Poikiloderma

Completed
Conditions
Poikiloderma
Registration Number
NCT02862834
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Brief Summary

In the context of this study, the investigators wish to take advantage of high-throughput genetic techniques (microarray and high-throughput exome sequencing) to identify new genes implicated in syndromic poikiloderma so as to improve the diagnostic decision tree in these syndromes, opportunities for genetic counselling for patients and their families and the follow-up of patients, notably with regard to the risk of tumours.

This study will make it possible to identify new genes implicated in syndromic poikiloderma and improve the diagnostic strategy proposed to patients with these syndromes, and to propose to patients a confirmed diagnosis, appropriate follow-up, notably with regard to the risk of tumours, genetic counselling to families and eventually an antenatal diagnosis to couples who would like to have one for future pregnancies.

The identification of new genetic causes of syndromic poikiloderma will also make it possible to complete the current classification of these syndromes

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
39
Inclusion Criteria

patients with syndromic poikiloderma, defined by the association of poikiloderma with other extradermatological clinical signs,

  • normal array-CGH, screening for chromosomal rearrangements,
  • absence of mutations in the genes RECQL4, KIND1 or C16orf57,
  • sporadic or familial involvement.
Exclusion Criteria
  • None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Identification of novel genes involved in syndromic poikilodermaday 1
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Dijon Bourgogne

🇫🇷

Dijon, France

CHU Dijon Bourgogne
🇫🇷Dijon, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.